Canadian-headquartered M Pharmaceutical has announced plans to continue advancing the development of a topical drug product as part of its planned acquisition of 40 J’s.
The drug will be used for the treatment of female sexual dysfunction (FSD).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
M Pharmaceutical USA CEO Thompson said: “Unlike the other two drugs approved by the US FDA to treat FSD, our topical drug product would focus on women with orgasm and arousal difficulties.
“Valeant’s Addyi, recently acquired from Sprout Pharmaceuticals, is indicated only for HSDD (desire disorder) with a number of FDA imposed prescription and marketing restrictions.
“Intrarosa, by Endoceutics, is indicated for dyspareunia (pain with intercourse) with certain prescribing restrictions.”
The company’s proposed treatment is topical, local and non-systemic, while being non-hormonal and is not a central nervous system drug.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataM Pharmaceutical noted that based on these core attributes, the product is expected to be well tolerated and effective for women suffering from FSD. It is also likely to be approved by the US Food and Drug Administration.
M Pharmaceutical develops technologies for obesity and weight management.
The company recently acquired a reformulation of orlistat C-103 from Chelatexx and its current focus will be on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction to treat obesity.
